SNX-111 neuron-specific calcium channel blocker: The FDA has placed a hold on a Phase II trial in 50 patients due to reports of recumbent hypotension

The company said the condition is not unexpected in severely traumatized patients, although it

Read the full 140 word article

How to gain access

Continue reading with a
two-week free trial.